Brief: Geneuro FY operating revenues rise to 5.9 million euros

Geneuro SA

27/04/2017 17:31

April 27 (Reuters) - Geneuro SA  GNRO.PA : 
    * Top-Line results from phase IIb multiple sclerosis trial 
expected early Q4 2017 
    * Cash and cash equivalents amounted to EUR 34.5 million at 
December 31, 2016, compared with EUR 18.6 million at December 
31, 2015 
    * FY operating revenues EUR 5.9 million versus EUR 2.5 
million year ago 
    * Fy net loss EUR 14.1 million versus loss of EUR 4.5 
million year ago 
    * Release intermediate six-month results for GNBAC1 is 
expected early in Q4 of 2017 
    * Fy operating loss EUR 14.0 million versus loss of EUR 4.3 
million year ago 
    * Plans to launch a clinical trial in progressive forms of 
MS by year-end 2017 
    * Plans to launch a clinical trial in progressive forms of 
MS in the us for GNBAC1 by year-end 2017 
    * Expects results of Australian phase II study in GNBAC1 
clinical development expansion to type I diabetes in Q3 2018 
 
Source text for Eikon:  ID:nBw3h1302a  
Further company coverage:  GNRO.PA  
 
 (Gdynia Newsroom:) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))